• Skip to main content
  • Skip to footer

Life Sciences British Columbia

  • Members Area |
  • Contact Us
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
    • LSBC Hall of Fame
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login

Chinook Therapeutics Inc.

Member Profile

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

Sector
Biotechnology, Therapeutics
Area of Expertise
  • Therapeutics
This member is looking for Academic Partnerships , Business Development
Company Stage Clinical Stage, Public Company
Stock Ticker KDNY - NASDAQ

Member Profile

Biotechnology, Therapeutics

Chinook Therapeutics Inc.

Silver Sponsor

Chinook therapeutics gray text green logo
  • Website www.chinooktx.com/
  • Email info@chinooktx.com
  • Address
    210-887 Great Northern Way
    Vancouver, BC
    V5T 4T5
  • Leadership Contact
    Eric Dobmeier, President & CEO
    Follow us:
  • Twitter
  • LinkedIn
  • News
  • Jobs

February 15, 2023

Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commerical Officer

May 24, 2022

Chinook Therapeutics Announces Pricing of a $105 Million Public Offering

November 9, 2021

Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering

June 8, 2021

Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IGA NEPHROPATHY (IGAN) at The 58th ERA-EDTA Virtual Congress

May 13, 2021

Chinook Therapeutics to Present at The 2021 RBC Capital Markets Global Healthcare Conference

No current content.

  • Twitter
  • Linkedin
Tweets by Chinook Therapeutics Inc.
Connect with us LinkedIn

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us